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Protective immunity differs 
between routes of administration 
of attenuated malaria parasites 
independent of parasite liver load
Simone Haeberlein  1,4, Séverine Chevalley-Maurel  1, Arifa Ozir-Fazalalikhan1, Hester 
Koppejan1, Beatrice M. F. Winkel1, Jai Ramesar1, Shahid M. Khan1, Robert W. Sauerwein3, 
Meta Roestenberg1,2, Chris J. Janse1, Hermelijn H. Smits1 & Blandine Franke-Fayard1
In humans and murine models of malaria, intradermal immunization (ID-I) with genetically attenuated 
sporozoites that arrest in liver induces lower protective immunity than intravenous immunization 
(IV-I). It is unclear whether this difference is caused by fewer sporozoites migrating into the liver or 
by suboptimal hepatic and injection site-dependent immune responses. We therefore developed 
a Plasmodium yoelii immunization/boost/challenge model to examine parasite liver loads as well 
as hepatic and lymph node immune responses in protected and unprotected ID-I and IV-I animals. 
Despite introducing the same numbers of genetically attenuated parasites in the liver, ID-I resulted 
in lower sterile protection (53–68%) than IV-I (93–95%). Unprotected mice developed less sporozoite-
specific CD8+ and CD4+ effector T-cell responses than protected mice. After immunization, ID-I mice 
showed more interleukin-10-producing B and T cells in livers and skin-draining lymph nodes, but fewer 
hepatic CD8 memory T cells and CD8+ dendritic cells compared to IV-I mice. Our results indicate that 
the lower protection efficacy obtained by intradermal sporozoite administration is not linked to low 
hepatic parasite numbers as presumed before, but correlates with a shift towards regulatory immune 
responses. Overcoming these immune suppressive responses is important not only for live-attenuated 
malaria vaccines but also for other live vaccines administered in the skin.
Malaria remains a major threat to the lives of more than 3 billion people world-wide. There is a pressing and 
yet unmet need for an effective vaccine that provides a high degree of sustained protection. Despite decades of 
clinical testing of (recombinant) sub-unit vaccines, only modest protection has been achieved so far. As a conse-
quence, the interest in whole organism malaria vaccine approaches has been renewed1–4.
Induction of complete protective immunity in humans has only been achieved by immunization with 
live attenuated Plasmodium sporozoites1, 5, 6 or by (non-attenuated) sporozoites that are administered under 
chemoprophylaxis7, 8. Attenuated sporozoites induce strong protective immune responses both in rodents9, 10 
and in humans5, 6, 11. Injected sporozoites need to be alive and to retain capacity to invade hepatocytes to induce 
protective immunity. Most immunization studies in rodent models have been conducted using the intravenous 
(IV) route of administration of sporozoites and only a few studies have analyzed alternative techniques such 
as intradermal (ID), intramuscular (IM) or subcutaneous (SC) injection of sporozoites12–18. However, the latter 
techniques will be more amenable for large-scale administration to infants in endemic countries. For vaccines in 
general there is renewed interest in the intradermal route of administration driven by the fact that the dermis and 
epidermis of human skin are rich in antigen-presenting cells, suggesting that delivery of vaccines to these layers 
should be more efficient and induce protective immune responses with smaller amounts of vaccine antigen19.
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Unfortunately, immunization by ID, IM or SC injections of attenuated sporozoites of both rodent (P. berghei, 
P. yoelii) and human (P. falciparum) malaria parasites induced lower levels of protective immunity compared to 
IV administration16, 20–23. In rodent malaria models, reduced potency was linked to a lower number of parasites 
in the liver (30–50 fold) after ID immunization (ID-I) compared to IV immunization (IV-I)12, 13, 17, 24. The impor-
tance of the number of sporozoites in the liver, i.e. the parasite liver load, for protective immunity is emphasized 
by the observations that high level protection can be achieved after ID-I provided that sufficiently high numbers 
of sporozoites are injected17, 24. This suggests that induction of protection mainly associates with the number of 
attenuated sporozoites reaching the liver and infecting hepatocytes25–31.
Protective immunity induced by immunization with sporozoites is associated with expansion of IFN-γ pro-
ducing CD8 memory T cells in the liver13, 32–35. Lower CD8 T cell responses were found after ID-I compared to 
IV-I which was explained by the lower parasite loads in the liver after ID-I13. Therefore, it has been speculated that 
the differences between ID-I and IV-I are the result of fewer parasites entering the liver after ID-I14. However, it 
is unknown whether the differences in protective immunity between ID-I and IV-I can be exclusively explained 
by differences in parasite liver loads or whether other immunological factors associated with the route of admin-
istration of sporozoites can also influence the induction of protective immune responses. Some authors favor the 
view that sporozoites deposited in the skin use the lymphatic system and thereby pass through lymph nodes to 
reach the liver36, 37.
In order to study the effect of the route of sporozoite administration on development of protective immune 
responses we developed a mouse model to compare sporozoite IV-I and ID-I, parasite liver load and immune 
responses in protected and in unprotected animals.
Unexpectedly, we found that at similar parasite liver loads, ID immunization resulted in lower protection 
compared to IV immunization. ID-I mice had less liver CD8 T cell effector responses and a stronger activa-
tion of immune cells with regulatory phenotype, compared to IV-I mice. We provide evidence that suboptimal 
protective efficacy by ID-I compared to IV-I cannot be solely explained by differences in parasite liver load. 
Our data indicate that the lower protective immunity results from different immune responses induced by ID 
immunization in skin-draining lymph node and liver compared to IV immunization. This may be the result of 
an immune-evasion strategy developed by the malaria parasite and understanding and countering this possible 
immune-evasion strategy should help in development of skin-based vaccination strategies for whole organism 
approaches of mosquito-borne diseases. Therefore while the skin remains an attractive target for immunization as 
it possesses an abundance of antigen presenting cells, our study indicates that this route can also negatively affect 
protective immune responses by generating immunosuppressive or modulatory responses after immunization, 
which has clear implications beyond malaria vaccines.
Results
Reduced protection by ID immunization compared to IV immunization despite similar para-
site liver loads. To investigate whether the low protective immunity after ID-I compared to IV-I can only 
be explained by differences in liver load we developed a P. yoelii mouse model to examine parasite liver loads 
and immune responses in the same animal. We generated a P. yoelii attenuated parasite line that lacks the fabb/f 
gene (PY17X_1126500) and in addition expresses the reporter protein GFP-Luciferase under control of the con-
stitutive eef1a promoter (ΔPyFabBF-GFP-Luccon parasites; Fig. S1). This transgenic line shows wild-type (wt) 
progression through the complete parasite life-cycle38–40. Deletion of the fabb/f gene in P. yoelii results in atten-
uated parasites that arrest late during liver stage development41 and allows for quantification of liver loads by 
measuring luciferase signals without the need of sacrificing the animal42. Using quantification of liver loads by in 
vivo imaging 44 hour after ID and IV administration of attenuated sporozoites we established that administration 
of 5 times more sporozoites ID (50 K) than IV (10 K), resulted in comparable liver loads and a high percentage of 
protected mice (>90%) after IV-I, using a primary and one boost immunization. With this regime similar parasite 
liver loads were obtained both after the primary immunization and the boost immunization 14 days later (Fig. 1).
To compare the level of protection, IV-I and ID-I mice with similar liver loads were challenged 14 days later 
with 10 K wt-Py-GFP-Luccon. sporozoites IV or by bite of mosquito with wt-Py-GFP-Luccon. Wt-Py-GFP-Luccon 
parasites express GFP-Luciferase under control of the constitutive eef1a promoter, allowing quantification of par-
asite liver load after challenge by in vivo imaging. Protection was assessed by monitoring blood stage parasitemia 
in blood smears up to day 14 after challenge (see schedule in Fig. S2). Despite comparable parasite liver load after 
IV-I and ID-I (Fig. 1C), only 68% of ID-I mice were protected compared to 93% upon IV-I. The ID-I and IV-I 
unprotected mice showed a comparable prepatent period of blood infection (on average 7 and 8 days, in the ID-I 
and IV-I mice, respectively (Fig. 1E). In comparison, naïve mice challenged with 10 K sporozoites show a prepat-
ent period of 4 days. A similar difference in protection between IV-I and ID-I mice was obtained when mice were 
challenged by infectious mosquito bite instead of needle inoculation (Fig. S3).
Artesunate treatment of challenged mice to determine immunization-induced immune responses in the liver inde-
pendent of blood stage infections in unprotected mice. To assess immunization-induced effects on liver immune 
responses without interference of immune responses induced by blood stage infections43, 44, blood stage develop-
ment should be avoided after challenge in unprotected mice. To this end, all IV- and ID-I mice were treated with 
the blood-stage killing drug artesunate starting at the day of challenge with wt sporozoites (see treatment scheme 
in Fig. S4). Absence of blood stages was confirmed by blood smears up to day 7 after challenge prior to organ 
collection. In these experiments protection was defined by the level of the parasite liver load in challenged mice as 
determined by in vivo imaging. Mice with RLU values lower than 4.104 (absence of bioluminescent signal) were 
considered protected and mice with RLU above 1.105 (clear bioluminescent signal) were considered unprotected. 
Mice showing ‘a weak spot’ of bioluminescence signal were excluded from the immunological analysis as outcome 
of protective immunity was doubtful. The parasite liver loads after primary immunization and boost were again 
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Figure 1. ID immunization with 50 K sporozoites results in same parasite liver load as 10 K IV but determines 
different outcome of protection. BALB/c mice were immunized with a liver-attenuated luciferase-expressing 
P. yoelii mutant (ΔPyFabBF-GFP-Luccon) by intravenous (IV) or intradermal (ID) inoculation of 10 K or 50 K 
sporozoites, respectively, followed by an IV or ID boost 2 weeks later. 44 h after primary immunization and 
boost, parasite liver loads were analyzed by in vivo imaging of luciferase activity. (A) In vivo images which show 
5 representative mice for each group after primary immunization and boost (parasite load measured as relative 
luminescence units, RLU, red color indicates high parasite load). (B) Summary of luciferase activity of 48 (10 K 
IV) and 43 (50 K ID) mice after primary immunization from 6 experiments. ns: no significance as determined 
by unpaired t-test. ns, not significant. (C–E) BALB/c mice were IV or ID immunized and challenged IV 
with 10 K luciferase-expressing wild-type (wt) P. yoelii sporozoites (Py-GFP-Luccon) 2 weeks after boost (see 
treatment scheme in Fig. S2). 44 h after immunization, boost or challenge, parasite liver loads were analyzed 
by in vivo imaging of luciferase activity. Blood smears were analyzed from day 4–14 after challenge to assess 
prepatency times. (C) Cumulative results from two separate experiments (n = 18, IV inoculation; n = 20, ID 
inoculation and n = 8, naïve) of liver load measured by luciferase activity. (D) In vivo images of 5 representative 
mice per group. (E) Protection rate and days of prepatency summarized for 4 experiments. All naïve mice 
infected with wt parasites developed blood infections.
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Figure 2. Level of protection in IV and ID immunized mice treated with artesunate (ART) after challenge with 
wild type parasites. BALB/c mice were immunized by IV or ID route. From the day of wt sporozoite challenge, 
mice were treated with artesunate to prevent development of blood stages in mice (see treatment scheme in 
Fig. S4). 44 h after primary immunization, boost or challenge, parasite liver loads were quantified by in vivo 
imaging of luciferase activity. (A) Luciferase activity of 5 representative mice from the ID immunized group 
www.nature.com/scientificreports/
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comparable in IV-I and ID-I mice and after challenge, we again observed a comparable difference in protec-
tion as observed without artesunate treatment; i.e. 53% and 95% protection in ID-I and IV-I mice, respectively 
(Fig. 2). Because drug treatment itself may modulate immune responses45, 46 and thereby influence the detection 
of immunization-induced responses, we compared several hepatic immune parameters at day 7 after challenge 
of naïve and IV-I mice both with and without artesunate treatment. In protected IV-I mice comparable responses 
were detected for CD8 and CD4 memory T cell induction, T cell interferon (IFN)-γ expression, and B cell inter-
leukin (IL)-10 expression, whereas a trend, though not significant, for lower frequencies of IL-10-expressing 
Foxp3+ regulatory T (Treg) cells in artesunate treated mice in both naïve and protected IV-I mice (Fig. S5). These 
results indicate that artesunate treatment can be applied for prevention of blood stage infection after challenge 
without affecting hepatic immune responses in experiments described below.
Unprotected ID-I mice show reduced effector and higher regulatory hepatic immune responses 
compared to ID-I and IV-I protected mice. To explain a differential protection outcome despite a com-
parable parasite liver load, we hypothesized that protected and unprotected ID-I mice may display differences in 
hepatic immunity. We therefore studied the hepatic immune responses in ID-I mice treated with artesunate to 
exclude any interference of blood stage parasitemia in the unprotected mice. Subsequently, ID-I hepatic immune 
responses were compared to those found in IV-I mice.
Unprotected ID-I mice show less CD8 and CD4 T cell effector responses compared to protected mice but similar 
CSP-antibody titers. T cell effector responses are crucial for protection in human and animal models21, 47–51 and 
might therefore explain the differential protection outcome. At day 7 after challenge, IFN-γ secretion of total 
hepatic leukocytes in response to ‘circumsporozoite protein’ peptide (CSP) and sporozoites was indeed 3.1-fold 
higher in protected compared to unprotected ID-I mice (Fig. 3A). Intracellular flow cytometric analysis revealed 
that CD8 T cells were the main source for CSP-specific IFN-γ, showing significantly more IFN-γ in protected 
compared to unprotected ID-I mice (Fig. 3B,C), which was similar to levels found in protected IV-I animals (indi-
cated by dotted line). In CD4 T cells, IFN-γ was not even upregulated compared to naïve mice which could be due 
to insufficient restimulation by CSP peptide, as opposed to polyclonal stimulation (Fig. S6B). Furthermore, the 
frequency of CD8 T cells expressing tumor necrosis factor alpha (TNF) and surface-exposed CD107a (a surrogate 
marker for cytotoxic activity) was higher in protected ID-I compared to unprotected ID-I mice (Fig. 3D,E), while 
expression of the cytolytic enzyme granzyme B in CD8 T cells did not differ between groups (Fig. S6A). As for 
CD8 T cells, also the CD4 T cell population showed a higher TNF and CD107a expression in protected ID-I mice 
(Fig. 3D,E), Interestingly, when applying a polyclonal stimulation by PMA/ionomycin, IFN-γ and TNF produc-
tion by CD8 and CD4 T cells were largely similar between protected and unprotected ID-I animals (Fig. S6B,C), 
suggesting specific differences for Plasmodium-specific T cell responses only. Next, we compared the induction 
of memory T cells in protected and unprotected ID-I animals. The frequency of total CD44+ (memory) T cells in 
livers of unprotected mice was equal (CD8 T cells) or even higher (CD4 T cells) compared to protected ID-I mice 
(Fig. S6D). However, the CD8 memory T cell frequencies (mean 41.2%) were significantly less compared to those 
of protected IV-I mice (50.8%, indicated by dotted line) pointing to a different capacity to induce T cell memory 
by different routes of immunization. Next to hepatic T cell responses, we checked for differences in peripheral 
blood mononuclear cells (PBMC) between protected and unprotected ID-I mice and similar for the livers, we 
observed that T cell effector responses in peripheral blood were stronger upregulated in protected mice than 
unprotected mice compared to naïve controls (Fig. S7).
Next to cellular components, antibody responses have been associated with protection by whole (attenu-
ated) sporozoite immunization and increased anti-CSP titers were shown to reduce liver parasite burden in a 
dose-dependent manner52, 53. However, we did not find significant differences in CSP-induced plasma antibody 
titers between protected or unprotected mice (Fig. S8), indicating that CSP-specific antibodies do not play a role 
in the observed difference in protection after ID and IV-I.
Taken together, despite similar hepatic parasite loads during immunization, unprotected mice developed 
mostly weaker CD4 and CD8 T cell effector responses compared to protected mice in both liver and peripheral 
blood, while CSP antibody titers were comparable.
Unprotected ID-I mice have higher regulatory immune responses compared to protected mice. Regulatory T cell 
responses can suppress the development of pro-inflammatory T cell responses54, 55 and might provide an expla-
nation for the observed lower T cell effector response and suboptimal protection efficacy by ID immunization. 
However, hepatic Treg cell frequencies, cell numbers, and intracellular IL-10 expression upon restimulation with 
CSP and sporozoites were comparable between protected and unprotected ID-I mice (Fig. 4B and Fig. S9A,B). 
Next to Treg cells, also Foxp3-negative CD4 T cells can fulfill regulatory function56. Indeed, unprotected mice had 
a significantly higher frequency of IL-10-expressing Foxp3-negative CD4 T cells compared to protected ID-I mice 
visualized after primary immunization, boost and challenge. (B) Summary of luciferase activity during the 
immunization/challenge protocol of mice immunized by the IV and ID route, and of challenged naïve mice. 
(C) Protection rates from 2 experiments. Based on the luciferase activity after challenge, mice were grouped 
into protected (luciferase negative) and unprotected (luciferase positive). ns: no significance, *p < 0.05 as 
determined by unpaired t-test. (D) Mice were immunized by ID route and challenged with wt sporozoites 
under artesunate treatment. Development of liver stages was analyzed by in vivo imaging at 44 h after primary 
immunization, boost, or challenge. Based on the luciferase activity after challenge, mice were grouped into 
protected and unprotected. Summary of 19 ID immunized mice.
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(3.4% vs. 2.3%) (Fig. 4A,B). Interestingly, the IL-10 expression of CD4 T cells from protected ID-I animals was 
still significantly higher compared to protected IV-I mice (in average 2.3% vs. 1.7%), and the same held true for 
B cell IL-10 expression (2.9% vs. 2.0%; Fig. S8C), supporting the idea of a generally higher IL-10 induction after 
ID immunization compared to the IV route. Also the regulatory markers CTLA-4 and GITR were significantly 
higher expressed on Foxp3-negative CD4 T cells of unprotected ID-I mice compared to protected ID-I mice, 
while Treg cells showed only a small but significantly higher expression for CTLA-4 but not GITR (Fig. 4C,D). 
Additionally IFN-γ secretion of total leukocytes negatively correlated with CTLA-4 (correlation coefficient −0.5 
and p = 0.049; Fig. 4E). Collectively, these data indicate a stronger hepatic regulatory immune response being 
induced in unprotected ID-I animals which inversely correlated with a reduced T cell effector response.
ID immunization induces less effector and more regulatory hepatic immune responses com-
pared to IV immunization during the immunization schedule. Using the IV and ID immunization 
protocol that resulted in similar liver loads, we found a suboptimal protection by the ID route compared to IV 
route that was associated with a suboptimal induction of effector immune responses together with increased 
Figure 3. Unprotected mice after ID immunization show reduced liver T cell effector responses compared to 
protected mice. ID immunized mice were challenged followed by artesunate treatment, and distinguished as 
protected (p, i.e. luciferase negative) or unprotected (unp, i.e. luciferase positive). Hepatic CD8 and CD4 T cells 
were analyzed at day 7 after challenge. (A) IFN-γ concentration in supernatant of total leukocytes after culture 
for 36 h with CSP and sporozoites as measured by ELISA. (B) Representative FACS plots of CD8+ gated T cells 
for intracellular expression of IFN-γ or TNF after culture for 4 h with CSP and brefeldin A, and for surface 
expression of CD107a after 4 h culture with CSP, brefeldin A and monensin. Numbers indicate the frequency 
of the gated cell population. Graphs show a summary of 2 experiments with 8–14 mice per group for frequency 
of IFN-γ (C), TNF (D), or CD107a (E) -expressing CD8 T cells and CD4 T cells. The dotted line indicates the 
mean cytokine or expression level for protected IV immunized mice (N = 9–16). Significant difference by 
Mann-Whitney test is indicated by *p < 0.05, **p < 0.01, ***p < 0.001 (to naïve control group), and #p < 0.05, 
##p < 0.01 (between immunized mouse groups).
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Figure 4. Unprotected mice have higher regulatory immune responses compared to protected mice. Hepatic 
CD4 T cells (gated Foxp3−) and Foxp3+CD25+ Treg cells of protected and unprotected ID immunized mice 
were analyzed for regulatory marker expression at day 7 after challenge under artesunate treatment. (A) 
Representative FACS plots of Foxp3− gated CD4 T cells for intracellular IL-10 expression after 36 h culture 
of hepatic leukocytes with CSP and sporozoites and addition of PMA/ionomycin plus brefeldin A in the 
last 4 h, and for surface expression of CTLA-4 or GITR ex vivo. Graphs show a summary of (B) intracellular 
IL-10 expression, (C) surface CTLA-4 and (D) GITR expression of Foxp3− CD4 T cells and Treg cells from 
2 experiments with 8–14 mice per group. The dotted line indicates the mean frequency for protected IV 
immunized mice (N = 9–16). Significant difference by Mann-Whitney test is indicated by *p < 0.05, **p < 0.01, 
***p < 0.001 (to naïve control group), and #p < 0.05, ###p < 0.001 (between immunized mouse groups). (E) 
The production of secreted IFN-γ by hepatic leukocytes was correlated with the percentage of hepatic CTLA4+ 
Foxp3− CD4 T cells. Correlation coefficient and p-value are indicated.
www.nature.com/scientificreports/
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regulatory responses in livers of unprotected ID-I mice. These responses were measured 7 days after challenge and 
we wondered whether the differences in immunity by the different routes of immunization were already induced 
at an earlier stage, i.e. after the primary immunization or after boost immunization.
ID-I mice have less activated hepatic CD44+ CD8 T cells compared to IV-I mice. A fast activation of T cells in 
response to antigen during immunization with whole sporozoites is a critical step to achieve protection32, 47, 48, 57–59. 
Therefore, expression of effector molecules and the T cell activation marker CD44 was analyzed 7 days after IV 
or ID primary immunization and after boost immunization, without subsequent challenge. A significant increase 
was observed of the total CD8 T cell population and the frequency of activated or memory CD44+ and CD44+ 
CD45RB+ CD8 T cell subsets within hepatic leukocytes compared to naïve controls. However, after the boost, this 
increase was significantly smaller in ID-I mice compared to IV-I mice, which is also reflected by a lower number 
of CD44+ CD8 T cells per liver (38% or 38.9 × 103 CD44+ CD8 T cells compared to 53% or 68.3 × 103; Fig. 5A–E; 
Table S1). CD44+ CD4 T cell frequencies were equally upregulated in IV-I and ID-I mice (Fig. 5F). Next, we eval-
uated CD8 T cell effector functions. Upon restimulation by PMA/ionomycin, IFN-γ expression was significantly 
higher in IV-I mice after boosting compared to ID-I mice (Fig. S10A), but CSP-specific IFN-γ and cytolytic 
enzyme granzyme B expression were equally upregulated in both IV-I and ID-I mice (Fig. S10B,C).
Because of the lower increase in activated T cells in ID-I mice after boosting we tested for T cell exhaustion 
during ID-I as an explanation for the observed suboptimal protection rates. The major inhibitory receptor regu-
lating T cell exhaustion, programmed cell death-1 (PD-1), is known to play a role in a strong reduction of CD8 T 
cell numbers (and function) during malaria infections60. In our ID-I and IV-I mice, expression of PD-1 was to a 
similar extent upregulated on both CD8 T cells and CD4 T(reg) cells compared to naïve controls (Fig. S11A–C). 
The ligand PD-L1 was even higher expressed on CD11chiMHCII+ conventional DCs in IV-I mice compared 
to ID-I mice (Fig. S11D). These observations indicate that a difference in T cell exhaustion between ID and IV 
immunizations does not account for the observed differences in the level of protection. Collectively, ID-I induced 
equally high parasite-specific CD8 T cell effector functions in the liver, but resulted in less activated CD8 T cell 
subset formation compared to IV-I, which is unlikely to be caused by differences in T cell exhaustion.
CD8 dendritic cell subset frequencies are lower in ID-I mice compared to IV-I mice. Suboptimal CD8 T cell acti-
vation may result from suboptimal priming by CD8+ dendritic cells (DC)34. Earlier studies showed that IV-I 
leads to accumulation of CD8+ DC in liver with a highly developed T cell memory inducing capacity34, 61. We 
therefore analyzed both conventional DC (cDC) and monocyte-derived DC (mo-DC) populations in liver after 
IV or ID primary immunization and boost immunization to investigate whether differences in these cell popu-
lations could explain the lower CD8 T cell activation observed in ID-I animals. Both after the primary and boost 
immunization the frequency of CD11chiMHCII+ cDC as well as CD11cintMHCII+CD64hi mo-DC within hepatic 
leukocytes was similarly increased in IV-I and ID-I mice compared to naïve controls (Fig. 6B). Although a similar 
increase was found in the number of CD8+ cDC and CD8+ mo-DC after the primary immunization in both ID-I 
and IV-I mice compared to naïve controls, these numbers were only further increased after boosting in the IV-I 
mice resulting in lower CD8+ DC frequencies and numbers in ID-I mice compared to IV-I mice (Fig. 6C,D). In 
contrast to the DC subset composition, there was no difference with respect to intracellular IL-12p40 expression, 
which was similarly upregulated in cDC after boost in both IV-I and ID-I mice (Fig. 6E). Combined, these data 
indicate a suboptimal recruitment of CD8+ DC subsets in the liver after ID immunization which might be linked 
to the suboptimal activation of CD8 T cells.
ID-I induces stronger regulatory immune responses in the liver compared to IV-I. Because we had observed a 
higher IL-10 production in both B and T cells after challenge in ID-I mice, we next investigated whether regula-
tory responses are already upregulated after primary immunization and boost immunization which may explain 
the differences in DC and activated T cell subset induction observed between IV-I and ID-I mice. To this end, 
hepatic leukocytes were collected 7 days after IV or ID primary and boost immunization and analyzed for regu-
latory marker expression. Similar as observed after challenge, the frequency, number and CSP-specific IL-10 and 
PD-1 expression of Foxp3+CD25+ Treg cells was equal in livers of IV-I and ID-I mice (Fig. 7A–C; Fig. S10C), 
making it unlikely that differences in number and activation of Foxp3+ Treg cells can explain the observed dif-
ferences between ID and IV immunization. In contrast to Treg cells and similar to what was found after chal-
lenge, the frequency and cell number per liver of IL-10-expressing Foxp3-negative CD4 T cells was significantly 
higher in ID-I mice after primary immunization compared to IV-I mice (in average 2.8% or 13.4 × 103 versus 
1.0% or 3.9 × 103 IL-10+ cells; Fig. 7D–F; Table S1). Also the number of CTLA-4-expressing CD4 T cells was 
higher in ID-I mice (Table S1), although this was not reflected by cell frequencies which were similarly increased 
by both immunization routes as it was the case for GITR (Fig. S12A,B). To draw conclusions on the nature of 
IL-10-expressing Foxp3-negative T cells, we performed a double-staining for IL-10 and IFN-γ (Fig. S12C). The 
results show that the frequencies of both IL-10-producing subsets, IL-10/IFN-γ double positive and IL-10 single 
positive, are significantly higher in ID compared to IV immunized animals (Fig. S12D). Both subsets are similar 
abundant in ID animals, which suggests that different types of regulatory IL-10-expressing CD4 T cells are pres-
ent, amongst which the type 1 regulatory (Tr1) cells which are characterized by IL-10 but no or very low IFN-γ 
expression56.
Interestingly, B cells showed a similarly increased IL-10 expression as Foxp3-negative T cells in ID-I mice after 
primary immunization compared to IV-I mice (2.2-fold higher frequency; 20.4 × 103 cells per liver compared to 
13.2 × 103), which returned to baseline levels after the boost immunization in both groups (Fig. 7G,H; Table S1). 
Thus, ID-I led to a higher IL-10 production in CD4 T cells and B cells, compared to IV-I. Interestingly, this was 
particularly evident after the primary immunization, preceding the suboptimal DC and T cell subset induction 
which was only observed after the boost immunization.
www.nature.com/scientificreports/
9ScIentIfIc REPORtS | 7: 10372  | DOI:10.1038/s41598-017-10480-1
Figure 5. Induction of activated CD44+ CD8 T cells is less by ID compared to IV immunization. BALB/c 
mice were immunized twice 2 weeks apart with liver-attenuated luciferase-expressing ΔPyFabBF-GFP-Luccon 
sporozoites (PyGAP) either with 10 K IV or 50 K ID. Expression of the activation and memory markers CD44 
and CD45RB on hepatic T cells at day 7 after primary immunization or boost were analyzed by flow cytometry. 
(A) Representative FACS plots of CD8+ and CD4+ gated T cells after IV or ID boost compared to a naïve 
control. Numbers indicate the frequency of the gated cell population. (B) Frequencies of CD8+ T cells within 
total CD3+ T cells, of (C) CD44hi cells and (D) CD45RBlow CD44hi cells within the CD8 T cell population, (E) 
number of CD44hi CD8 T cells per liver, and (F) of CD44hi cells within the CD4 T cell population. Summary of 2 
experiments with 8–10 mice per group. Significant difference by Mann-Whitney test is indicated by **p < 0.01, 
***p < 0.001 (to naïve control group), and ##p < 0.05, ##p < 0.01 (between immunized mouse groups).
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Lymph node regulatory responses are increased by ID-I compared to IV-I. After ID immunization, the 
skin-draining lymph node is one of the first sites of immunological responses, and may influence protection out-
come or shape down-stream immunity in liver. Because we had observed increased regulatory responses in liver 
7 days after primary ID-I, we investigated whether the same holds true for cells of the inguinal lymph node drain-
ing at the site of sporozoite administration (Table S2). We find increased frequencies of IFN-γ producing CD4+ 
and CD8+ T cells in ID-I compared to IV-I mice (Fig. 8A). However, in addition we find significantly increased 
Figure 6. CD8 dendritic cell subset frequencies are smaller after ID compared to IV immunization. Dendritic 
cell (DC) subsets in liver were analyzed by flow cytometry at 7 days after primary or boost immunization via IV 
or ID route. (A) MHCII+CD11chi/int DC were gated for CD11cintCD64hi monocyte-derived DC (mo-DC) and 
CD11chiCD64low conventional DC (cDC) after excluding F4/80-expressing macrophages. Representative FACS 
plots of both DC subsets for CD8 and intracellular IL-12p40 expression in mice 7 days after IV or ID boost or 
in naïve control mice are shown. Numbers indicate the frequency of the gated cell population. (B) Frequencies 
of DC subsets within total leukocytes. (C) Number of CD8-expressing DC per liver. (D) Frequencies of CD8-
expressing DC within the mo-DC or cDC subset. (E) Intracellular IL-12p40 expression of DC subsets after 
culture of leukocytes with brefeldin A for 4 h. Summary of 2 experiments with 8–10 mice per group. Significant 
difference by Mann-Whitney test is indicated by *p < 0.05, **p < 0.01, ***p < 0.001 (to naïve control group), 
and #p < 0.05, ##p < 0.01 (between immunized mouse groups).
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frequencies and cell numbers of several IL-10-expressing cell types in lymph nodes (B cells, Foxp3− CD4 T cells, 
Foxp3+ Treg cells) (Fig. 8B). The same was true for the frequency of CTLA-4-expressing Foxp3- CD4 T cells 
(Fig. 8C). Thus, next to IFN-γ producing T cells, ID-I also substantially increases regulatory responses in both, 
liver and skin-draining lymph nodes.
Taken together, ID-I not only induced suboptimal protection compared to IV immunization, but also led to 
increased frequencies of IL-10 producing B and T cells in lymph nodes and liver as well as to suboptimal hepatic 
CD8 (memory) T cell immune responses, a defect already detected during immunization in ID-I mice and which 
remained detectable after challenge in the group of unprotected ID-I mice. Importantly, these differences in pro-
tective efficacy and protective immunity developed despite comparable parasite livers load between both immu-
nization routes.
Figure 7. ID immunization induces stronger regulatory immune responses in liver compared to IV. Hepatic 
leukocytes were analyzed 7 days after IV or ID primary immunization or boost for regulatory marker 
expression by flow cytometry directly ex vivo (A,B) or after 36 h culture with CSP and sporozoites (C–G). (A) 
Number of Foxp3+CD25+ Treg cells per liver. (B) Frequency of Treg cells within the CD4+ T cell population. 
(C) Intracellular IL-10 expression of Treg cells after addition of PMA, ionomycin and brefeldin A for 4 h to the 
culture. (D) Representative FACS plots of CD4+ Foxp3-negative T cells (CD4 T) in one IV or ID immunized 
and a naïve control mouse. (E,F) Summary of intracellular IL-10 expression of CD4+Foxp3− T cells after 
addition of PMA, ionomycin and brefeldin A expressed as frequencies (E) and cell number per liver (F). 
Representative FACS plots (G) and summary (H) of intracellular IL-10 expression in CD19+ gated B cells after 
addition of PMA, ionomycin and brefeldin A. Graphs show 1 representative out of 2 similar experiments (C) 
or a summary of 2 experiments with 8–10 mice per group. Significant difference by Mann-Whitney test is 
indicated by *p < 0.05, **p < 0.01, ***p < 0.001 (to naïve control group), and #p < 0.05, ##p < 0.01 (between 
immunized mouse groups).
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Discussion
A prerequisite for induction of protective immunity by immunization with injected sporozoites is that they are 
alive and retain the capacity to invade hepatocytes. In both human and mouse studies the number of sporozoites 
administered correlates with the level of protective immunity, and in mouse models the level of parasite liver 
loads associates with the level of protection. Based on these observations, it has been assumed that the parasite 
liver load after immunization is the most critical factor in determination the level of protective immunity.
Figure 8. ID but not IV immunization increases regulatory immune responses in the skin-draining lymph 
node. Inguinal lymph node cells were analyzed 7 days after IV or ID primary immunization for regulatory 
marker and cytokine expression. Flow cytometry was performed after 36 h culture with CSP and sporozoites 
and addition of PMA, ionomycin and brefeldin A in the last 4 h (A,B), or directly ex vivo (C). Frequencies 
calculated relative to naïve control are given for (A) IFN-γ+ CD4 T cells and CD8 T cells, (B) IL-10+ Foxp3− 
CD4 T cells, IL-10+ Foxp3+CD25+ Treg cells, IL-10+ CD19+ B cells, and (C) CTLA-4+ Foxp3− CD4 T cells and 
CTLA-4+ Foxp3+CD25+ Treg cells. Summary of 2 experiments with 10 mice per group. Significant difference 
by unpaired t-test is indicated by *p < 0.05, **p < 0.01, ***p < 0.001 (to naïve control group), and ##p < 0.01, 
###p < 0.001 (between immunized mouse groups).
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In contrast to what has been suggested in previous studies we found that differences in protection outcome 
and hepatic immune response between IV and ID immunization are not exclusively explained by differences in 
liver load. Our data provide new insights on the immunization-induced activation and recruitment of specific cell 
subsets into liver, an understudied organ in terms of immunological consequences of sporozoite immunization. 
This involves, amongst others, antigen-specific CD8 T cell responses, mo-DC as well as IL-10-producing T and B 
cells as likely critical determinants in protection outcome.
It is generally accepted that CD8 T cells play a central role in protective immunity induced by immunization 
with live sporozoites in rodent malaria models. Our data support this important role as unprotected mice had 
weaker antigen-specific CD8 T cell effector responses both in liver and peripheral blood. While we could not 
detect differences in IFN-γ expression by CD8 T cells induced by the different routes of immunization (Figs 3C, 
S10B), we found higher frequencies of CD8 T cells and CD8 memory T cells in IV-I mice compared ID-I. This 
could be explained by an increased CD8 T cell division which might play a role for protection outcome in our 
immunization/boost/challenge model. Similarly, in a recently published study applying adoptive transfer of 
Plasmodium-specific CD8 T cells prior to IV or ID injection of sporozoites, IV led to higher cell division of 
antigen-specific CD8 T cells in liver and hepatic lymph nodes than ID administration62. With respect to CD4 T 
cells, recent observations in individuals vaccinated with RTS-S, a recombinant CSP-based vaccine, and in indi-
viduals naturally exposed to malaria suggest an important role for CD4 T cell production of TNF, with or without 
IFN-γ, as a potential immune correlate of protection63. This is in line with our findings where CD4 T cell expres-
sion of TNF was only induced in protected but not unprotected animals.
Next to T cells, also CD8+ DC were found to accumulate in liver after IV immunization with 
radiation-attenuated sporozoites and these cells were highly potent in driving development of CD8 memory T 
cells ex vivo and to confer protection upon adoptive transfer61, 64. Also in our IV-I mice the frequency of CD8+ 
cDC increased from low steady-state frequencies up to about 15% within the total DC population after boosting, 
a similar level as obtained after immunization with radiation-attenuated sporozoites61. Interestingly, after boost-
ing both CD8 DC and CD44+ CD8 T cell subset frequencies were significantly lower in ID-I mice compared 
to IV-I animals, suggesting a positive correlation between low DC and T cell responses and weak development 
of protective immunity by ID immunization. However, it is well established that T cells can also be primed by 
DCs within the skin-draining lymph node and then recirculate to the liver, at least after exposure to sporozoites 
through infected mosquito bites65. Although mosquito-bite is not exactly comparable to ID administration, a 
similar phenomenon of DC priming in skin-draining lymph node might occur as well after ID immunization. 
Thus, while we found several significant differences in liver for both DC and T cell subsets between ID and IV 
immunization which might be related to differences in the level of protection, it is still unclear where T cell prim-
ing by DC occurs.
In contrast to conventional DC, surprisingly little is known about the role of monocyte-derived DC during 
malaria infection and immunization. We provide the first indication that mo-DC accumulate in the liver and that 
the extent of accumulation is influenced by the immunization route. Also in other protozoan or viral infection 
models, mo-DC were shown to accumulate at the site of infection and contribute to CD4 T cell and CD8 memory 
T cell induction66, 67. This is in line with the concept of local DC differentiation, in which circulating precursors 
give rise to DC subsets in peripheral organs. Interestingly, in studies of microbial and viral infections it was found 
that mo-DC efficiently cross-present antigen to CD8 T cells, that T cell priming can be even more powerful than 
by conventional CD8+ DC and that T cell priming was enhanced by linking TLR agonists to an antigen68, 69. These 
observations warrants further studies on malaria-associated mo-DC and poses novel opportunities to improve 
malaria vaccine efficacy by designing mo-DC-enhancing antigens or adjuvants as part of a general strategy to 
support vaccination against infectious diseases70.
Several studies have described induction of regulatory responses during malaria infections in various organs 
by malaria infected red blood cells (iRBCs). Improved clearance of iRBCs has been observed in the absence of 
Treg-derived IL-1071, 72. Only few studies have addressed regulatory cells after immunization71, 73, 74. Unfortunately, 
those studies do not provide insight whether the observed regulatory responses are only a consequence of blood 
stage infections or can already be induced by the pre-erythrocytic stages, i.e. the sporozoites and the liver stages. 
To rule out the effect of blood stage infection and iRBCs on the induction of regulatory responses we treated 
immunized mice after challenge with wt parasites with artesunate to prevent the development of blood stage 
infections in unprotected mice. We found increased regulatory responses in the liver of unprotected ID-I mice, 
which show that regulatory responses in these mice were induced without blood-stage infections. We demon-
strated that after wt challenge unprotected mice have higher frequencies of activated Foxp3+ Treg cells in liver, 
showing increased CTLA-4 expression compared to protected mice. In mice with P. yoelii blood stage infections 
another IL-10 producing but Foxp3-negative regulatory T cell type termed Tr1 cells was found to suppress clear-
ance of iRBC71, 75. Here, we found that also in the absence of blood stages unprotected ID-I mice have higher 
frequencies of Foxp3-negative CD4 T cells with regulatory phenotype (IL-10, CTLA-4, GITR) compared to those 
cells in protected ID-I mice, and this expression was negatively correlated with IFN-γ expression, suggesting the 
induction of regulatory and suppression of proinflammatory immune responses by pre-erythrocytic stages. Our 
data thus indicate that the ratio of pro- versus anti-inflammatory markers (such as IFN-γ, TNF vs IL-10, CTLA4) 
associates with control of liver infection after immunization. This might be true also for humans in which control 
of blood stage infection associated with the ratio of TNF versus IL-1076–78.
Another important player in the network of regulatory cells are regulatory B (Breg) cells. Despite the atten-
tion that Breg cells have attracted in studies of other infectious or inflammatory diseases, including protozoan 
infections79, 80, Breg cells have so far largely been understudied in studies of malaria infections. Regulatory B 
cells usually express high levels of IL-10 and have been linked to immune responses in different disease states, 
such as regulation of auto-immunity, allergic disease and helminth infections81–83. As far as we know, only one 
study has addressed the induction of IL-10 producing B cells during malaria infections, in which these cells were 
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detected in spleens of mice with P. berghei blood stage infection and were associated with controlling cerebral 
pathology84. Our study provides the first evidence that IL-10 producing B cells are also induced in skin-draining 
lymph node and liver upon immunization with sporozoites, and our observations show that ID immunization 
leads to stronger induction of these cells compared to IV immunization, very similar to what we observed for 
IL-10 producing Foxp3-negative T cells.
An important question is how the elevated frequencies of different IL-10 producing cell types we observed in 
this study might affect immunity in ID-I mice. It has been recently described that IL-10 promotes the maturation 
of memory CD8 T cells during bacterial and viral infection85, 86, while other studies showed that IL-10 sup-
pressed memory induction in acute bacterial, viral and parasitic infections85–87. We observed a weaker induction 
of CD44+ CD8 (memory) T cells in ID-I mice compared to IV-I mice, both after boosting and after challenge. 
Interestingly, IL-10 induction occurred already after primary immunization and thus preceded the suboptimal 
DC and memory T cell subset induction in ID-I mice. In particular, we found IL-10-expressing CD4 T cells with 
characteristics of type 1 regulatory (Tr1) T cells (Foxp3 negative, high IL-10, no/low IFN-γ expression). This 
antigen-specific subset is known to be induced by antigen exposure, such as during infection or immunization, 
from naïve CD4 T cells in the periphery, and to subsequently suppress Th1 responses56. This subset might be piv-
otal in suppressing malaria protective immunity in our model, as was described for other protozoan infections88. 
Furthermore, we found regulatory and effector responses to negatively correlate with each other after challenge 
of the mice. Because we could not find support for alternative explanations of the low protective efficacy of ID 
immunization, such as increased T cell exhaustion or low parasite-specific antibody titers, it is tempting to spec-
ulate that regulatory immune cells play a dominant role in suppressing the development of DC and effector T cell 
function.
ID immunization apparently favors development of IL-10 expression in liver, as frequencies of IL-10 express-
ing CD4 T cells and B cells were higher in ID-I mice already after primary immunization compared to IV-I 
mice. This might indicate that certain immune evasion mechanisms are initiated by ID administered sporo-
zoites. IV administered sporozoites reach the liver within minutes89, whereas it is known that most ID admin-
istered sporozoites remain in the skin for hours before entering the bloodstream and invading a hepatocyte90. 
Sporozoites remaining in the skin at the site of administration might be associated with the development of 
regulatory responses which we found in skin-draining lymph nodes of ID-I mice, such as increased IL-10 expres-
sion by CD4 T cells next to IFN-γ producing T cells, suggesting the existence of a balance between regulators 
and effectors, which may boil down into differential migration or activation of hepatic responses, explaining why 
some ID-I mice are still protected and others not. For instance, local high levels of IL-10 at the site of sporozoite 
administration might contribute to a reduced induction of cytotoxic T cell responses by affecting function of der-
mal DC, a subset which has been described as principal migratory DC and being capable of efficiently presenting 
Plasmodium antigens and activating CD8 T cells in dermal lymph nodes91. Furthermore, cytotoxic T lymphocyte 
responses induced by transcutaneous immunization in a tumor model were counter-regulated by both regulatory 
T cells and IL-1092. The concept of regulatory immune responses being induced by skin-administered malaria 
vaccines is not new. It was proposed that regulatory skin responses might subsequently suppress protective liver 
immunity93. Expanding this concept, our data now suggest that regulatory cell types are not only induced in the 
skin as the site of vaccine administration, but also in the skin-draining lymph node and, importantly, in the liver 
itself. If regulatory cell types, in skin, lymph node or liver, are indeed contributing to the low protection by ID 
immunization needs to be addressed in future studies. This is the more important, as also in volunteers that were 
immunized with attenuated sporozoites94, 95, unprotected individuals displayed increased Treg cell proliferation 
in peripheral blood already after boost immunization. Although these activated regulatory cell types differ from 
those found in our study, these observations indicate an adverse role of activation of regulatory cells for protective 
immunity.
Dissecting regulatory responses will be essential to improve the protective immunity induced ID immuniza-
tion. Only increasing the sporozoite immunization dose in ID-vaccination approaches may not be sufficient for 
obtaining levels of protection that are comparable to IV-vaccination with attenuated sporozoites. Novel (trans)
dermal delivery techniques and adjuvants may need to be explored. Examples of adjuvants that are known to 
increase ID vaccine immunogenicity are synthetic immunostimulatory agents (like cytosine phosphoguanosine, 
CpG) in Hepatitis B vaccination96 or the application of imiquimod (Aldara cream), a synthetic toll-like receptor 
agonist which stimulates pro-inflammatory cytokine production and innate immunity at site of administration in 
influenza vaccination97. Although regulatory responses have not been analyzed in these studies, it is attractive to 
speculate on the capacity of these adjuvants to overcome immunoregulatory processes, leading to a more potent 
induction of sterile protection.
In summary, we demonstrate that (1) the parasite liver load is not decisive for low levels of protection after 
ID-I compared to IV immunization, that (2) different types of hepatic immune responses are induced by IV- 
versus ID-I, with a preferred induction of regulatory hepatic T and B cells and a suboptimal CD8 memory T cell 
responses after ID immunization, and that (3) also in the skin-draining lymph node ID-I favors upregulation 
of regulatory immune responses. Understanding the suppressive immune responses after skin administration 
of sporozoites will be essential to improve ID immunization with attenuated sporozoites. Targeted inhibition of 
regulatory T and B cell function or prevention of their development may allow for the induction of more potent 
protective T cell responses by ID administered sporozoites and should help in development of skin-based vacci-
nation strategies.
Materials and Methods
Experimental animals and wild type and transgenic P. yoelii lines. Female BALB/cByJ mice 
(6–7 weeks; Charles River, NL and Harlan, Bicester, UK) were used. All animal experiments of this study were 
approved by the Animal Experiments Committee of the Leiden University Medical Center (DEC 13132 and 
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14307). The Dutch Experiments on Animal Act is established under European guidelines (EU directive no. 
86/609/EEC regarding the Protection of Animals used for Experimental and Other Scientific Purposes). All 
experiments were performed in accordance with relevant guidelines and regulations. Two P. yoelii (Py) lines 
were used: i) the reference ‘wild type’ Py17XNL parasite line 1971cl1 (Py-GFP-Luccon; line RMgm-689; www.
pberghei.eu) which contains the fusion gene gfp-luc gene under control of the constitutive eef1α promoter inte-
grated into the silent 230p gene locus (PY17X_0306600) and does not contain a drug-selectable marker and 
ii) a Py17XNXL mutant that lacks the gene fabb/f (3-oxoacyl-acyl-carrier protein synthase; PY17X_1126500). 
This mutant (ΔPyFabBF-GFP-Luccon; mutant RMgm-4109; www.pberghei.eu) was generated in the reference 
line 1971cl1 (see above) by standard methods of transfection98 using a DNA construct that targets the fabb/f gene 
by double cross-over integration. The 5′- and 3′- fabb/f target regions were amplified using primers 7358 5′-atg-
ggcccTTGCGCTATTTATAAGAGTTTGAGAGG/7359 5′-aaggcctCAAGAATATTTTTAAGGGCCATTTC and 
7360 5′-ccggggtaccCAATGATTGCAAATACACCATCAG/7361 5′-ataagaatgcggccgcGTGGATATACGCAAGT-
GTGCGAG and cloned up (ApaI/StuI) and downstream (KpnI/NotI) of the hdhfr/fcu selectable marker cassette 
of plasmid pL0034 (MRA-849, www.beiresources.org). The final DNA construct was linearized with HindIII/
EcoRI before transfection. Transfection, selection and cloning of transformed parasites was performed using 
standard genetic modification technologies98 using Py 1971cl1 as the parent parasite line. Cloned parasite lines 
were obtained (exp. 2251; ΔPyFabBF-GFP-Luccon) by the method of limiting dilution. Correct integration of 
DNA construct and disruption of gene was verified by Southern analyses of Pulsed Field Gel (PFG)-separated 
chromosomes and PCR analysis98. PFG-separated chromosomes were hybridized with a mixed probe of the 
human dhfr gene99 and ~800 bp fragment of 5′UTR of PBANKA_0508000 located on chromosome 5100. Primers 
used to confirm by PCR correct integration of the construct are listed in Fig. S1.
Mosquito infection, preparation and injection of sporozoites. Sporozoites were obtained by man-
ual dissection of the salivary glands of infected female Anopheles stephensi mosquitoes 14 days after feeding on 
infected mice. Mosquitoes were kept at a temperature of 24.5 °C and 80% humidity. Salivary glands were collected 
in RPMI medium, homogenized and filtered (40 µm Falcon, Corning, Amsterdam, NL). The free sporozoites were 
counted in a Bürker counting chamber using phase-contrast microscopy. For IV administration sporozoites were 
suspended in RPMI medium and per mouse 200 μl was injected into the tail vein. For ID administration sporo-
zoites were also suspended in RPMI medium and per mouse 20 µl was injected (10 µl at each upper thigh). For ID 
injection 30 G × 8 mm needles (BD Micro-Fine, BD Biosciences, Breda, NL) were used and prior to administra-
tion of sporozoites, mice were anesthetized using isoflurane and shaved to optimize ID administration.
Immunization protocol and prepatent period after challenge. For the immunization-challenge 
experiments mice were immunized with a primary immunization on day 0 and a boost immunization on day 14 
using isolated ΔPyFabBF-GFP-Luccon sporozoites. For IV immunization 10 K sporozoites were used and for IV 
immunization 50 K ID. Blood of immunized mice was analyzed for possible breakthrough blood infections by 
Giemsa-stained blood smears after each immunization. Immunized mice and naïve controls were challenged 14 
days after the last immunization with 10 K wt Py-GFP-Luccon sporozoites or by bite of 10 infected mosquitoes. 
Challenged mice were monitored for blood-stage infections by Giemsa-stained blood smear during days 4–14 
after challenge. The prepatent period (measured in days after sporozoite challenge) is defined as the day when 
a blood stage infection with a parasitemia of 0.5–2% is observed. Organs used for immunological analysis were 
collected 7 days after sporozoite immunization or 7 days after challenge.
Artesunate treatment of challenged mice. Artesunate powder (Sigma-Aldrich, Zwijndrecht, NL) was 
dissolved in 5% sodium bicarbonate (NaHCO3) in drinking water of the mice. Based on a daily intake of mice of 
4–7 ml drinking water per day15, we used a concentration of 0.3 mg/ml artesunate in the drinking water resulting 
in a daily oral dose of 1.2 to 2.1 mg (60 mg/kg bodyweight). This dose has been shown to effectively kill blood 
stage parasites in rodent malaria46. The drug in the drinking water was given to mice at the day of challenge until 
organ dissection for analysis of immune responses.
Determination of parasite liver load after immunization and challenge by real time in vivo imaging. 
Parasite liver loads in live mice were quantified by real time in vivo imaging as previously described101, 102. Liver 
stages were visualized and liver loads quantified by measuring luciferase activity of parasites in whole bodies of 
mice at 44 h after injection of sporozoites using the IVIS Lumina II Imaging System (Perkin Elmer Life Sciences, 
Waltham, USA). Before measurements the fur from bellies of the mice were shaved and during measurements 
mice were anesthetized using the isofluorane-anesthesia system (XGI-8, Caliper Life Sciences, Hopkinton, USA). 
D-luciferin was dissolved in PBS (100 mg/kg; Caliper Life Sciences, USA) and injected subcutaneously in the 
neck. Measurements were performed within 8 minutes after the injection of D-luciferin. Quantitative analysis of 
bioluminescence of whole bodies was performed by measuring the luminescence signal intensity using the ROI 
(region of interest) settings of the Living Image® 4.4 software.
Liver perfusion and cell purification. Mice were perfused under anaesthesia by intracardiac injection 
of 20 ml phosphate buffered saline (PBS, B. Braun, Oss, NL). Perfused livers were minced in small pieces and 
digested for 45 min at 37 °C in HBSS (Thermo Fisher Scientific, Breda, NL) containing 1 mg/ml type IV colla-
genase from Clostridium histolyticum, 2000 U/ml DNase 1 (both Sigma-Aldrich, NL) and 1 mM CaCl2. Single-cell 
suspension was obtained by passing the digested tissue through a 100 µM cell-strainer, and hepatocytes removed 
by centrifugation at low speed (50x g, 3 min). The supernatant containing hepatic leukocytes was centrifuged at 
1500 rpm, 10 min, and red blood cells lyzed in the cell pellet by 2 min incubation with cold lysis buffer (0.15 M 
NH4Cl, 1 mM KHCO3, 0.1 mM Na2EDTA in PBS). PBS supplemented with 1% heat-inactivated fetal calf serum 
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(FCS; Greiner Bio-One, Alphen aan den Rijn, NL) and 2.5 mM EDTA (Sigma-Aldrich) was used for rinsing 
and washing steps. Leukocytes were isolated by positive selection using anti-CD45 Microbeads (Miltenyi Biotec, 
Leiden, NL; 35 µl beads per liver). Purity was generally >95%.
Blood collection. Blood (~500–700 μl) was collected from the orbital sinus of anaesthetized mice into 
heparin-coated tubes. After red blood cell lysis by 5 min incubation with cold lysis buffer, PBMC were obtained 
for subsequent in vitro culture or flow cytometric analysis.
Collection of lymph node cells. Inguinal lymph nodes were digested for 20 min in RPMI (1640 glutamax; 
Thermo Fisher Scientific) containing Collagenase D (1 mg/ml; Roche Life Science, Almere, The Netherlands) and 
DNase 1 (400 U/mL; Sigma-Aldrich) at 37 °C. Single-cell suspension was obtained by passing the digested tissue 
through a 100 µM cell-strainer.
In vitro cultures of hepatic leukocytes, PBMC or lymph node cells. For detection of intracellu-
lar cytokines and cytotoxicity-related proteins, hepatic leukocytes, PBMC or lymph node cells (2.5 × 106/ml) 
were cultured in medium (RPMI 1640 glutamax; Thermo Fisher Scientific), containing 5% FCS, 5 × 10−5 M 
2-Mercaptoethanol (Sigma-Aldrich) and antibiotics (100 U/ml penicillin and 100 μg/ml streptomycin; both 
Sigma-Aldrich). P. yoelii circumsporozoite peptide (CSP; SYVPSAEQI103) (10 µg/ml) was added for 4 h for flow 
cytometric detection of IFN-γ, TNF, IL-12p40, granzyme B and CD107a. Either brefeldin A (10 µg/ml) or a com-
bination of brefeldin A, phorbol myristate acetate (PMA, 100 ng/ml) and ionomycin (1 μg/ml) (all Sigma-Aldrich) 
was added to the cells as indicated in the figure legends. For the detection of intracellular IL-10 it was required to 
culture cells with CSP peptide (10 µg/ml) plus P. yoelii sporozoites (Py wt-GFP-Luccon, 25,000/ml) for 36 h includ-
ing PMA, ionomycin and brefeldin A in the last 4 h. For flow cytometric detection of surface-exposed CD107a, 
cells were cultured for 4 hours with 0.25% GolgiStop (BD Biosciences), 10 µg/ml brefeldin A and anti-mouse 
CD107a-AlexaFluor488 (eBioscience, Vienna, Austria). For the detection of secreted IFN-γ, cells were cultured 
with CSP peptide and P. yoelii sporozoites for 36 h prior to collection of supernatants.
Flow cytometry. Cells were stained with the live/dead marker Aqua (Thermo Fisher Scientific) and fixed 
with the eBioscience Foxp3/Transcription Factor kit or with 1.9% paraformaldehyde (Sigma-Aldrich). For the 
surface staining of the degranulation marker CD107a, cells were left unfixed and directly processed for flow 
cytometric analysis. For intracellular staining, cells were permeabilized with the eBioscience kit or 0.5% sapo-
nin (Sigma-Aldrich). Flow cytometric analysis was performed by staining with fluorochrome-labeled antibodies 
against mouse CD3, CD19, CD44, CD45RB, CD107a, CTLA-4, F4/80, Foxp3, GzmB, IL-10, IL-12p40, MHCII, 
TNF (all eBioscience), CD11c, CD25, IFN-γ (BD Biosciences), and CD8, CD64, GITR, PD-1 and PD-ligand 1 
(Biolegend, Uithoorn, NL). For all flow cytometric stainings, FcγR-binding inhibitor (2.4G2) was added and 
fluorescence minus one (FMO) controls were used for gate setting. Flow cytometry was performed using a 
FACSCanto (BD Biosciences).
ELISA. After 36 h in vitro culture of hepatic leukocytes or PBMC with CSP peptide and P. yoelii sporozoites as 
described above, the concentration of IFN-γ in the culture supernatant was determined by a commercial ELISA 
kit according to the manufacturer’s instructions (BD Biosciences). Levels of CSP-antibodies in mice were deter-
mined by ELISA. Mouse sera of naïve mice were used as negative control. The 96-well ELISA plates were first 
coated with 10 K of lyzed wt Py-GFP-Luccon sporozoites overnight (pellet resuspended in NaHCO3 buffer (pH 
9,6)) overnight and then blocked with 1% BSA in PBS-Tween. Mouse sera were diluted (1/10 000) and added to 
the plates and incubated for 3 h. After washing the plates, HRP-conjugated rabbit anti-mouse IgG Fc Fragment 
was added (1/5000; incubation for 1 h). After TMB High Sensitivity Substrate was added, ODs were read at 
450 nm.
Statistics. Statistical analyses were performed using unpaired t-test or Mann-Whitney test with the 
GraphPad Prism software package 6.05 (GraphPad Software, Inc). One-sample t-test of log-transformed data was 
applied to calculate significant changes for data which are expressed as fold increase. Correlation coefficients were 
obtained by Spearman correlation analysis. p-values < 0.05 were considered significant. All data are presented as 
mean ± standard error of the mean (SEM).
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